Puma Biotechnology PBYI will host a conference call at 1:30 p.m. PST
(4:30 p.m. EST) on Monday, December 23, 2013, to provide an update on
its clinical trials of PB272 (neratinib) in cancer patients with
activating HER2 mutations. This includes the Company's ongoing trials of
neratinib in (1) patients with HER2 mutated non-small cell lung cancer;
(2) patients with HER2-negative breast cancer who have a HER2 mutation;
and (3) patients with solid tumors who have an activating HER2 mutation.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in